UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.72
+3.48%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.67
From 52W high−56.60%
Volume271985.00
Market cap$103.48M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.67
From 52W high
−56.60%
Volume
271985.00
Market cap
$103.48M
ValuationView details →
P/E (Fwd)
8.4x
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
41.7
MomentumView details →
1D Return
+3.48%
YTD Return
−36.22%
SummaryUpdated Jun 1, 2026
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) is a clinical-stage biotechnology company founded in 2016 and headquartered in Los Altos, California. The company went public in July 2021 and focuses exclusively on developing innovative therapeutic treatments for kidney diseases, an area of significant unmet medical need. As a pre-revenue biotech company, Unicycive is currently advancing its pipeline of kidney-focused drug candidates through various stages of clinical development, with its lead programs targeting chronic kidney disease complications and acute kidney injury.
Similar companies
Latest newsMore news →
Law Offices of Howard G. Smith announced a lawsuit alleging that Unicycive Therapeutics, Inc. failed to disclose key facts to investors during the period from December 29, 2025, through June 29, 2026.13d agoThe U.S. Food and Drug Administration accepted Unicycive Therapeutics, Inc.’ resubmitted new drug application for oxylanthanum carbonate and set a PDUFA target action date of March 25, 2027.14d agoA class action lawsuit was filed against Unicycive Therapeutics on behalf of investors who acquired its securities during the stated class period.14d ago